**Abstract**

**Background:** Anxiety symptoms are common in patients with major depressive disorder (MDD) and are associated with greater severity, impaired functioning, and less favorable outcomes. The objective of this open-label study was to explore the effects of adjunctive brexpiprazole in patients with MDD and anxiety symptoms (NCT02013531).

**Methods:** Patients with MDD and anxiety symptoms (HAM-A≥20) with an inadequate response to current ADT were enrolled and received open-label ADT+brexpiprazole 1 to 3mg/day (2mg/day target dose) for 6 weeks. Efficacy endpoints included change in clinician-rated MADRS and HAM-A total score from baseline to Week 6, and change in the 92-item patient-rated Kellner Symptom Questionnaire (KSQ, range 0 to 92) total score from baseline to Week 6.

**Results:** A total of 37 patients were treated with brexpiprazole+ADT, of these 32 patients completed 6 weeks of treatment. Improvements were observed for the LS mean change in MADRS total score from Baseline to Week 6 in patients treated with brexpiprazole+ADT (least square mean change: -19.6) and in HAM-A total score (-17.8). In addition, the mean change from Baseline to Week 6 in KSQ total score (-29.4) also improved. Adjunctive brexpiprazole was well tolerated; the incidence of activating adverse events (akathisia, restlessness, agitation, anxiety, and insomnia) was low (≤5%); and no clinically relevant changes in the mean laboratory test values, vital signs, or ECG parameter values were observed.

**Conclusion:** Adjunctive treatment with brexpiprazole may represent a novel and effective strategy for treatment of patients with MDD and symptoms of anxiety showing an inadequate response to ADT.
